Your address will show here +12 34 56 78
Press Releases, Press Releases

Cannabis & CBD’s Revenue Net Positive and a Look at MCIG Inc Business Model

NEW YORK, NY / ACCESSWIRE / January 31, 2017 / Traders News Source, an equity research firm specializing in small and micro-cap securities, is looking at recent events with mCig, Inc. (MCIG), a diversified company servicing legal cannabis, hemp, and CBD markets. Results for the quarter ended October 2016, were reported on December 21st, 2016. MCIG’s results were significantly better than expectations.

Get the financial details for the recent quarter at MCIG in the full report READ HERE

(Copy and paste to your browser may be required

MCIG has reached an important inflection point of controlled expenses, improved off take, and overall profitability. It has signed minimum order quantity contracts with its overseas partners, which is expected to provide medium term revenue visibility. Also, the company’s profit margin on product sales has improved to roughly 20% of internet sales and 28% of wholesale. Improved profitability coupled with initial revenues from construction, has finally led to a profitable quarter in October for MCIG.

MCIG reported better than expected results in all three operating segments i.e. construction, wholesale, and retail. Its construction division emerged as the most profitable one and the wholesale e-Cig and CBD segment continues to remain profitable and are presently positioned well in international & US markets. Over the years, MCIG has established itself in growing the Cannabis market and have become geographically diverse following the addition of new clients, new products roll outs, and continued market penetration via existing product lines and expanded distribution agreements.

In our full report we discuss the MCIG business model in detail READ HERE

(Copy and paste to your browser may be required


Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email Nadia Noorani a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

Comments are closed.